Effectiveness of Written Dietary Advice on Lipoproteins - a Pragmatic Randomized Controlled Trial

NCT ID: NCT03528252

Last Updated: 2019-04-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

113 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-05-16

Study Completion Date

2019-04-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study investigates the effect of detailed, written dietary advice for improving blood lipids, in a primary care setting. n=222 participants will be randomized to Active Intervention or Control Group. After 3 weeks' intervention, participants will receive written feedback on the effect on their blood lipids. After 6 months, another blood sample is drawn and participants will receive further written feedback.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The Active Intervention Group will receive detailed dietary advice based on current evidence for food choices that improve LDL cholesterol levels. The information will contain motivational strategies, e.g. "It's great that you want to improve your blood lipids! What are your three main reasons that you want to improve your blood lipids? What food choices suit you? How low can you go?" Participants will receive a table of ten suggested healthy food choices and be instructed to mark for each day a certain food change has been made.

The Control Group will receive similar advice and motivational strategies, with the one difference being the dietary advice, that will focus on Triglycerides instead of LDL cholesterol.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cholesterol, LDL

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Two identical parallel groups
Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Caregivers Investigators
Randomization by sealed envelopes, opened in private. Allocation sequence and envelopes provided by external agent. Participants are instructed not to discuss intervention outside household. No more than one (randomly selected) participant per household allowed.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LDL Cholesterol

Will receive dietary advice effective for reducing LDL cholesterol.

Group Type ACTIVE_COMPARATOR

Written advice LDL Cholesterol

Intervention Type OTHER

One A4 paper with written information on both sides

Triglycerides

Will not be aware that they are in fact Control Group. Will receive dietary advice effective for reducing Triglycerides, but neutral for LDL cholesterol.

Group Type SHAM_COMPARATOR

Written advice Triglycerides

Intervention Type OTHER

One A4 paper with written information on both sides

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Written advice LDL Cholesterol

One A4 paper with written information on both sides

Intervention Type OTHER

Written advice Triglycerides

One A4 paper with written information on both sides

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Active Intervention Control Group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Listed patient at Svärdsjö Primary Health Care Centre
* Willing to reduce blood lipids

Exclusion Criteria

* Drugs affecting blood lipids (statins, ezetimibe, fibrates, PCSK9-inhibitors, neuroleptic drugs, cortisone, amiodarone, estrogen, progesterone, testosterone, cyclosporin, tacrolimus, loop diuretics, protease inhibitors and anti-convulsants; whereas beta blockers, thiazide diuretics, and SGLT2-inhibitors are allowed under established medication
* Current malignant disease
* Extreme diet
* Abnormal metabolism e.g. uncontrolled hypothyroidism
* Dementia
* Unability to comprehend written information in Swedish
* Other participant from same household
* Current employment on Svärdsjö Primary Health Care Centre
Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Dalarna County Council, Sweden

OTHER

Sponsor Role collaborator

Uppsala University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

David Iggman

General practitioner, Principal Investigator, Associated researcher

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

David Iggman, M.D. Ph.D

Role: PRINCIPAL_INVESTIGATOR

Uppsala University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Svärdsjö Primary Health Care Centre

Falun, Dalarna County, Sweden

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Sweden

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Statistical Analysis Plan

View Document

Document Type: Study Protocol

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Dnr 2018/119

Identifier Type: OTHER

Identifier Source: secondary_id

MYDICLIN

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Oil Consumption and Cholesterol
NCT04397055 COMPLETED NA
Oat and Cholesterol
NCT03911427 COMPLETED NA